ClinicalTrials.gg
CompletedNCT05509816Updated Nov 12, 2025Results posted

A Study of Imlunestrant (LY3484356) in Healthy Women

A Phase 1 interventional study of Midazolam and Imlunestrant in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-12.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The main purpose of this study is to evaluate the effect of imlunestrant (LY3484356) when administered orally on the levels of midazolam in the blood stream in healthy women of non-childbearing potential. The study will also evaluate the safety and tolerability of imlunestrant in healthy women of non-childbearing potential. This study will last up to approximately 6 weeks for each participant including the screening period.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women not of
  • Participants who are overtly healthy as determined by medical assessment
  • Participants with (BMI) of 18.0 and 35.0 kilograms per meter squared (kg/m²), inclusive

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to imlunestrant, related compounds or any components of the formulation or midazolam
  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder
  • Use or intend to use medications that are substrate drugs of P-glycoprotein
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Midazolam + Imlunestrant

    Participants received 400 milligram (mg) Imlunestrant (2 × 200 mg) tablets administered once daily (QD) orally for 7 days on Days 3 to 9 and a single dose of 0.5 mg midazolam solution orally on Day 1 and Day 9 as per below dosing sequence: Day 1: 0.5 mg midazolam alone Days 3 to 8: 400 mg imlunestrant QD alone Day 9: 0.5 mg midazolam + 400 mg imlunestrant There was a washout period of 8 days between doses of midazolam.

    Drug: Midazolam · Drug: Imlunestrant

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam

    PK: AUC\[0-∞\] of Midazolam

    Time frame: Day 1: Predose, 0.25hours (h), 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose; Day 9: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24, 36, 48h postdose

  2. PK: Maximum Observed Concentration (Cmax) of Midazolam

    PK: Cmax of Midazolam

    Time frame: Day 1: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose; Day 9: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24, 36, 48h postdose

Secondary outcomes

  1. PK: AUC[0-∞] of 1'-Hydroxymidazolam

    PK: AUC\[0-∞\] of 1'-hydroxymidazolam

    Time frame: Day 1: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose; Day 9: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24, 36, 48h postdose

  2. PK: Cmax of 1'-Hydroxymidazolam

    PK: Cmax of 1'-hydroxymidazolam

    Time frame: Day 1: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose; Day 9: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24, 36, 48h postdose

  3. PK: Area Under the Concentration Versus Time Curve From Zero to 24 Hours at Steady State (AUC[0-24], ss) of Imlunestrant When Dosed in the Presence of Midazolam

    PK: AUC\[0-24\], ss of Imlunestrant

    Time frame: Day 9: Predose, 0.25 h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose

  4. PK: Maximum Observed Concentration at Steady State (Cmax, ss) of Imlunestrant When Dosed in the Presence of Midazolam

    PK: Cmax, ss of Imlunestrant when dosed in the presence of Midazolam is evaluated.

    Time frame: Day 9: Predose, 0.25 h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose

07

Results

Posted Nov 12, 2025

Participant flow

Participant flow — Overall Study
MilestoneMidazolam + Imlunestrant
Started20
Received at least one dose of study drug20
Completed19
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam

PK: AUC\[0-∞\] of Midazolam

Time frame:
Day 1: Predose, 0.25hours (h), 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose; Day 9: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24, 36, 48h postdose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam
nanogram*hour per milliliter (ng*hr/mL)0.5 mg Midazolam0.5 mg Midazolam + 400 mg Imlunestrant
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam12.3 ± 3211.4 ± 41
Statistical analysis
  • 0.5 mg Midazolam vs 0.5 mg Midazolam + 400 mg Imlunestrant · Mixed Models Analysis · Ratio of geometric least squares mean: 0.929 · 90% CI 0.849 to 1.02The least square means (LSMs) and differences in LSMs were back transformed to produce the geometric least square means (GLSMs) and ratio between GLSMs. These were reported along with the 90% confidence interval (CI) for the ratio.
PrimaryPK: Maximum Observed Concentration (Cmax) of Midazolam

PK: Cmax of Midazolam

Time frame:
Day 1: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose; Day 9: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24, 36, 48h postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of Midazolam
nanograms per milliliter (ng/mL)0.5 mg Midazolam0.5 mg Midazolam + 400 mg Imlunestrant
PK: Maximum Observed Concentration (Cmax) of Midazolam3.84 ± 354.12 ± 31
Statistical analysis
  • 0.5 mg Midazolam vs 0.5 mg Midazolam + 400 mg Imlunestrant · Mixed Models Analysis · Ratio of geometric least squares mean: 1.07 · 90% CI 0.989 to 1.16The LSMs and differences in LSMs were back transformed to produce the GLSMs and ratio between GLSMs. These were reported along with the 90% CI for the ratio.
SecondaryPK: AUC[0-∞] of 1'-Hydroxymidazolam

PK: AUC\[0-∞\] of 1'-hydroxymidazolam

Time frame:
Day 1: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose; Day 9: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24, 36, 48h postdose
Reported as:
Geometric mean · ng*hr/mL
PK: AUC[0-∞] of 1'-Hydroxymidazolam
ng*hr/mL0.5 mg Midazolam0.5 mg Midazolam + 400 mg Imlunestrant
PK: AUC[0-∞] of 1'-Hydroxymidazolam2.75 ± 402.26 ± 40
Statistical analysis
  • 0.5 mg Midazolam vs 0.5 mg Midazolam + 400 mg Imlunestrant · Mixed Models Analysis · Ratio of geometric least squares mean: 0.821 · 90% CI 0.777 to 0.868
SecondaryPK: Cmax of 1'-Hydroxymidazolam

PK: Cmax of 1'-hydroxymidazolam

Time frame:
Day 1: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose; Day 9: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24, 36, 48h postdose
Reported as:
Geometric mean · ng/mL
PK: Cmax of 1'-Hydroxymidazolam
ng/mL0.5 mg Midazolam0.5 mg Midazolam + 400 mg Imlunestrant
PK: Cmax of 1'-Hydroxymidazolam0.748 ± 400.722 ± 35
Statistical analysis
  • 0.5 mg Midazolam vs 0.5 mg Midazolam + 400 mg Imlunestrant · Mixed Models Analysis · Ratio of geometric least squares mean: 0.964 · 90% CI 0.828 to 1.12
SecondaryPK: Area Under the Concentration Versus Time Curve From Zero to 24 Hours at Steady State (AUC[0-24], ss) of Imlunestrant When Dosed in the Presence of Midazolam

PK: AUC\[0-24\], ss of Imlunestrant

Time frame:
Day 9: Predose, 0.25 h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose
Reported as:
Geometric mean · ng*hr/mL
PK: Area Under the Concentration Versus Time Curve From Zero to 24 Hours at Steady State (AUC[0-24], ss) of Imlunestrant When Dosed in the Presence of Midazolam
ng*hr/mL0.5 mg Midazolam + 400 mg Imlunestrant
PK: Area Under the Concentration Versus Time Curve From Zero to 24 Hours at Steady State (AUC[0-24], ss) of Imlunestrant When Dosed in the Presence of Midazolam2020 ± 53
SecondaryPK: Maximum Observed Concentration at Steady State (Cmax, ss) of Imlunestrant When Dosed in the Presence of Midazolam

PK: Cmax, ss of Imlunestrant when dosed in the presence of Midazolam is evaluated.

Time frame:
Day 9: Predose, 0.25 h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose
Reported as:
Geometric mean · ng/mL
PK: Maximum Observed Concentration at Steady State (Cmax, ss) of Imlunestrant When Dosed in the Presence of Midazolam
ng/mL0.5 mg Midazolam + 400 mg Imlunestrant
PK: Maximum Observed Concentration at Steady State (Cmax, ss) of Imlunestrant When Dosed in the Presence of Midazolam120 ± 51

Adverse events

Collected over Baseline Up to Day 18. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.5 mg Midazolam0/20 (0%)0/20 (0%)0/20 (0%)
400 mg Imlunestrant0/20 (0%)0/20 (0%)5/20 (25%)
0.5 mg Midazolam + 400 mg Imlunestrant0/20 (0%)0/20 (0%)1/20 (5%)
Most frequent other events
Most frequent other events
Event0.5 mg Midazolam400 mg Imlunestrant0.5 mg Midazolam + 400 mg Imlunestrant
DiarrhoeaGastrointestinal disorders0/203/201/20
HeadacheNervous system disorders0/202/200/20

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Midazolam + Imlunestrant
Mean50.8 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Midazolam + Imlunestrant
Female20
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Midazolam + Imlunestrant
Hispanic or Latino14
Not Hispanic or Latino6
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Midazolam + Imlunestrant
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White15
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Midazolam + Imlunestrant
United States20
08

Study locations

2 sites
  • LabCorp CRU, Inc.
    Daytona Beach, Florida 32117, United States
  • LabCorp CRU, Inc.
    Dallas, Texas 75247, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Nov 2022, 2 months.

Results were first posted in Nov 2025, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2022
First posted
Aug 22, 2022
StartActual
Sep 12, 2022
Primary completionActual
Nov 30, 2022
CompletionActual
Nov 30, 2022
Results first posted
Nov 12, 2025
Last update
Nov 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05509816
Responsible party
Sponsor
First posted
Aug 22, 2022
Start date
Sep 12, 2022
Primary completion
Nov 30, 2022
Completion
Nov 30, 2022
Results posted
Nov 12, 2025
Last update
Nov 12, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imlunestrant

Start the discussion